Hoffmann-La Roche: Autism Spectrum Disorder trials
The registry lists 10 Autism Spectrum Disorder studies with Hoffmann-La Roche as lead sponsor. 0 are open to participants now and 8 have results posted.
Phase 1 6Phase 2 3Phase 3 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy ParticipantsCompletedNCT04475848Phase 1Results posted
- A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)CompletedNCT04299464Phase 2Results posted
- A Study to Investigate the Effect of Esomeprazole and the Effect of Food on the Pharmacokinetics of Balovaptan in Healthy VolunteersCompletedNCT04156646Phase 1Results posted
- A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Balovaptan in Children With Autism Spectrum DisorderTerminatedNCT04049578Phase 1Results posted
- A Study to Evaluate Scales for Repetitive and Restricted Behaviors in Children, Adolescents, and Adults With Autism Spectrum Disorder (ASD)CompletedNCT03611075Phase 1Results posted
- Open Label, Adaptive, Parallel Group PET Study Using RO7017773 And [11C] RO15-4513CompletedNCT03507569Phase 1Results posted
- A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label ExtensionTerminatedNCT03504917Phase 3Results posted
- A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Participants With Autism Spectrum Disorder (ASD)TerminatedNCT02901431Phase 2Results posted
- The Effect of Hepatic Impairment on the Pharmacokinetics of BalovaptanWithdrawnNCT03912350Phase 1
- A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders (ASD)CompletedNCT01793441Phase 2